NasdaqGS:WGSHealthcare
GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives
GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches and data partnerships.
See our latest analysis for GeneDx Holdings.
Despite a sharp 1 day share price return of 4.8% decline and a 30 day share price return of 26.2% decline that suggest sentiment has cooled after the guidance update, the 1 year total shareholder return of 53.2% and a very large...